News Release Ariad Announces FDA Acceptance of NDA Filing for Ponatinib in CML and Ph+ALL
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 24, 2012-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for accelerated review of ARIAD’s investigational BCR-ABL inhibitor, ponatinib, in patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).